Neurologic Manifestations of Zika Virus Infection: What We Know So Far
Jonathan Miner, MD, PhD, and Karin Nielsen-Saines, MD, MPH, discuss the latest insights about neurologic complications of ZVI and knowledge gaps that still exist in this field.
All articles by Jasenka Piljac Žegarac, PhD
A Clinical Update on the Prevention, Treatment of Periprosthetic Joint Infections
Alberto V. Carli, MD, and Ashley E. Levack, MD, MAS, discuss preventive and treatment options for periprosthetic joint infections.
Addressing Palliative Care in Hepatocellular Carcinoma
Research shows that palliative care can help with symptom management, care coordination, therapeutic decision making, and the psychosocial aspects of living with hepatocellular carcinoma.
Transfusion-Transmitted Hepatitis B Virus: Minimizing the Risk
The risk for HBV transfusion-transmitted infection has been significantly reduced in the last few decades by the careful selection of donors and testing of blood donations, using sensitive serological and molecular screening techniques.
Managing HBV Infection Following Liver Transplant: Expert Q&A
In the past 2 decades, prophylactic antiviral therapies have drastically reduced the rates of HBV recurrence, allograft loss, and mortality in patients undergoing liver transplantation.
Universal Influenza Vaccine: A Game Changer in Prevention
A dedicated research effort led by NIH’s National Institute of Allergy and Infectious Diseases is aimed at developing a universal influenza vaccine that would confer better and longer-lasting protection against influenza virus strains.
Climate Change: Effects on the Incidence and Distribution of Infectious Diseases
Without proactive measures and response, the changing climate is projected to continue to adversely affect the global incidence and distribution of infectious diseases and cause 250,000 additional deaths per year between 2030 and 2050.
MicroRNAs in Infectious Disease: Emerging Clinical Applications
MicroRNAs are currently under investigation for various clinical applications in infectious disease because of their role in host response to infection and effects on innate and adaptive immune pathways.
Racial Disparities in HCV Incidence and Treatment Outcomes
Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.
Preventing HCV Transmission: Utility of Needle/Syringe Programs
Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject drugs in Europe and North America, respectively.
Next post in Hepatitis
